GlycoMimetics Financial Statements From 2010 to 2024

GLYC Stock  USD 0.24  0.01  4.00%   
GlycoMimetics financial statements provide useful quarterly and yearly information to potential GlycoMimetics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on GlycoMimetics financial statements helps investors assess GlycoMimetics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting GlycoMimetics' valuation are summarized below:
Gross Profit
75 K
Market Capitalization
15.5 M
Enterprise Value Revenue
126.9238
Revenue
10 K
Earnings Share
(0.62)
We have found one hundred twenty available fundamental trends for GlycoMimetics, which can be analyzed and compared to other ratios and to its competitors. Investors should ensure to confirm all of GlycoMimetics' regular performance against the performance from 2010 to 2024 to make sure the company is sustainable down the road. As of December 17, 2024, Market Cap is expected to decline to about 127.3 M. In addition to that, Enterprise Value is expected to decline to about 66.5 M

GlycoMimetics Total Revenue

9,500

Check GlycoMimetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GlycoMimetics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 217.6 K, Interest Expense of 56.3 M or Total Revenue of 9.5 K, as well as many indicators such as Price To Sales Ratio of 15.7 K, Dividend Yield of 0.0 or PTB Ratio of 1.98. GlycoMimetics financial statements analysis is a perfect complement when working with GlycoMimetics Valuation or Volatility modules.
  
Check out the analysis of GlycoMimetics Correlation against competitors.
For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.

GlycoMimetics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets88.5 M45.3 M77.6 M
Slightly volatile
Other Current LiabilitiesM5.2 M5.2 M
Slightly volatile
Total Current Liabilities9.5 M6.8 M9.2 M
Very volatile
Total Stockholder Equity36.5 M38.4 M64.4 M
Slightly volatile
Other Liabilities226 K237.9 K830.5 K
Slightly volatile
Property Plant And Equipment Net1.3 M767.8 K1.1 M
Slightly volatile
Current Deferred Revenue3.4 M3.6 M5.4 M
Slightly volatile
Accounts Payable1.5 M868.1 K1.4 M
Slightly volatile
Cash39.7 M41.8 M71.1 M
Slightly volatile
Non Current Assets Total2.2 M1.5 M1.9 M
Slightly volatile
Non Currrent Assets Other1.1 M757.9 K892 K
Slightly volatile
Cash And Short Term Investments39.7 M41.8 M71.1 M
Slightly volatile
Common Stock Total Equity59.2 K56.4 K30.6 K
Slightly volatile
Common Stock Shares Outstanding32.9 M63.3 M28.2 M
Slightly volatile
Liabilities And Stockholders Equity88.5 M45.3 M77.6 M
Slightly volatile
Non Current Liabilities Total63.5 K66.8 K1.3 M
Slightly volatile
Other Current Assets1.7 M1.8 M289.6 M
Pretty Stable
Other Stockholder Equity300.5 M494.8 M261.1 M
Slightly volatile
Total Liabilities10.6 M6.9 M10.4 M
Pretty Stable
Property Plant And Equipment Gross729.4 K767.8 K1.4 M
Slightly volatile
Total Current Assets86.3 M43.8 M75.7 M
Slightly volatile
Common Stock35.1 K64.4 K30.1 K
Slightly volatile
Property Plant Equipment876.5 K1.1 M787.7 K
Slightly volatile
Net Tangible Assets46.9 M49.4 M77.2 M
Pretty Stable
Net Receivables148.9 K175.8 K106.2 K
Slightly volatile
Capital Surpluse304.1 M503.3 M274.6 M
Slightly volatile
Net Invested Capital36.5 M38.4 M109.7 M
Slightly volatile
Net Working Capital35.1 M37 M108.4 M
Slightly volatile
Capital Stock56.2 K64.4 K47.2 K
Slightly volatile
Short and Long Term Debt Total1.6 M808.4 KM
Slightly volatile
Capital Lease Obligations1.6 M808.4 KM
Slightly volatile
Short Term Debt698.3 K741.6 K820 K
Pretty Stable

GlycoMimetics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization217.6 K153.3 K191.5 K
Slightly volatile
Other Operating Expenses41.2 M39.3 M35.9 M
Slightly volatile
Research Development29.5 M20.1 M25.8 M
Slightly volatile
Total Operating Expenses41.2 M39.3 M35.9 M
Slightly volatile
Selling General Administrative13.3 M19.2 M10.5 M
Slightly volatile
Non Operating Income Net Other786.3 K748.9 K376.8 K
Slightly volatile
Interest Income1.3 M2.2 M824.9 K
Slightly volatile
Reconciled Depreciation198.4 K175.7 K252 K
Slightly volatile
Net Interest Income1.4 M2.2 M2.5 M
Slightly volatile
Selling And Marketing Expenses510573624
Slightly volatile

GlycoMimetics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.6 M3.6 M3.1 M
Slightly volatile
Begin Period Cash Flow82.2 M47.9 M71.2 M
Slightly volatile
Depreciation217.6 K153.3 K191.5 K
Slightly volatile
Capital Expenditures20.3 K21.4 K181.5 K
Slightly volatile
End Period Cash Flow39.7 M41.8 M71.1 M
Slightly volatile
Sale Purchase Of Stock15.5 M16.3 M42.7 M
Slightly volatile
Change To Netincome4.9 M5.4 M3.8 M
Slightly volatile
Issuance Of Capital Stock27.1 M32.9 M83.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio15.7 K14.9 K2.7 K
Slightly volatile
PTB Ratio1.983.89152.3611
Pretty Stable
Days Sales Outstanding6.7 K6.4 K1.3 K
Slightly volatile
Book Value Per Share0.580.60653.5084
Slightly volatile
Average Payables1.2 M1.6 M1.4 M
Slightly volatile
Stock Based Compensation To Revenue37435663.6408
Slightly volatile
Capex To Depreciation0.130.13961.1765
Slightly volatile
PB Ratio1.983.89152.3611
Pretty Stable
Payables Turnover1.010.960.3681
Slightly volatile
Sales General And Administrative To RevenueK1.9 K313
Slightly volatile
Research And Ddevelopement To Revenue2.1 KK390
Slightly volatile
Capex To Revenue3.42.13943.066
Very volatile
Cash Per Share0.630.65986.056
Slightly volatile
Days Payables Outstanding3753952.4 K
Slightly volatile
Current Ratio7.06.40668.1628
Slightly volatile
Tangible Book Value Per Share0.580.60653.5084
Slightly volatile
Receivables Turnover0.0540.05691.6 K
Pretty Stable
Graham Number2.682.819412.2019
Slightly volatile
Shareholders Equity Per Share0.580.60653.5084
Slightly volatile
Capex Per Share3.0E-43.0E-40.0478
Slightly volatile
Average Receivables62.1 K65.4 K106.7 K
Pretty Stable
Revenue Per Share1.0E-42.0E-41.6837
Slightly volatile
Interest Debt Per Share0.440.80.7556
Pretty Stable
Price Book Value Ratio1.983.89152.3611
Pretty Stable
Days Of Payables Outstanding3753952.4 K
Slightly volatile
Ebt Per Ebit1.080.93950.9906
Very volatile
Company Equity Multiplier1.531.17971.5364
Slightly volatile
Quick Ratio6.096.406644.0565
Pretty Stable
Net Income Per E B T0.981.81.0738
Slightly volatile
Cash Ratio6.796.11437.9281
Slightly volatile
Days Of Sales Outstanding6.7 K6.4 K1.3 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.00061.0163
Pretty Stable
Price To Book Ratio1.983.89152.3611
Pretty Stable
Fixed Asset Turnover0.01240.01310.8399
Slightly volatile
Price Sales Ratio15.7 K14.9 K2.7 K
Slightly volatile
Asset Turnover2.0E-42.0E-40.1882
Slightly volatile
Price Fair Value1.983.89152.3611
Pretty Stable

GlycoMimetics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap127.3 M149.5 M147.2 M
Slightly volatile

GlycoMimetics Fundamental Market Drivers

Cash And Short Term Investments41.8 M

GlycoMimetics Upcoming Events

3rd of April 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About GlycoMimetics Financial Statements

GlycoMimetics stakeholders use historical fundamental indicators, such as GlycoMimetics' revenue or net income, to determine how well the company is positioned to perform in the future. Although GlycoMimetics investors may analyze each financial statement separately, they are all interrelated. For example, changes in GlycoMimetics' assets and liabilities are reflected in the revenues and expenses on GlycoMimetics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in GlycoMimetics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue3.6 M3.4 M
Total Revenue10 K9.5 K
Cost Of Revenue153.3 K145.6 K
Stock Based Compensation To Revenue 356.05  373.85 
Sales General And Administrative To Revenue1.9 KK
Research And Ddevelopement To RevenueK2.1 K
Capex To Revenue 2.14  3.40 
Ebit Per Revenue-3.9 K-3.7 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether GlycoMimetics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of GlycoMimetics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Glycomimetics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Glycomimetics Stock:
Check out the analysis of GlycoMimetics Correlation against competitors.
For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlycoMimetics. If investors know GlycoMimetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlycoMimetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.62)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.59)
Return On Equity
(1.04)
The market value of GlycoMimetics is measured differently than its book value, which is the value of GlycoMimetics that is recorded on the company's balance sheet. Investors also form their own opinion of GlycoMimetics' value that differs from its market value or its book value, called intrinsic value, which is GlycoMimetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlycoMimetics' market value can be influenced by many factors that don't directly affect GlycoMimetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlycoMimetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if GlycoMimetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlycoMimetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.